serum prostate-specific antigen (PSA) concentrations by 50%. The effect of 5-ARIs on prostate cancer detection in a PSA-screened population remains unclear. We tested the hypothesis that prediagnostic 5-ARI use is associated with a delayed diagnosis, more advanced disease, and higher risk of prostate cancer-specific mortality and all-cause mortality.
INTRODUCTION AND OBJECTIVES:
Benign prostatic hyperplasia (BPH) and associated lower urinary tract symptoms (LUTS) are a prevalent and progressive condition in aging men. To investigate the efficacy and safety of Afalaza in men with BPH at risk of progression the multicenter, double-blind, placebo-controlled, randomized clinical trial was performed. Derived by technological treatment of antibodies to prostate-specific antigen and endothelial NO synthase Afalaza was previously proved to modulate its molecular targets.
METHODS: 249 patients of 45-60 years old with BPH and moderate LUTS, total prostate volume (TPV) ! 30 cm 3 , maximum urine flow rate (Qmax) of 10-15 ml/s, and serum prostatic specific antigen (PSA) <4 ng/ml were randomly assigned to receive either Afalaza (n[125) or placebo (n[124) for 12 months. Interactive voice/web response randomization system based on a random number generator was used for patients`randomization. Changes in BPH/LUTS symptoms (according to the International Prostate Symptom Score [IPSS]), Qmax, TPV, PSA, BPH clinical progression, occurrence of acute urinary retention (AUR) events or BPH-related surgery were estimated as the study endpoints. The study was conducted in accordance with the all ethic principles and was approved by the National Ethics Committee.
RESULTS: IPSS mean (AEstandard deviation) change was -3.7AE3.0 (95% confidence interval (CI) -4.3 to -3.2) after 12 months of Afalaza (vs. -2.9AE2.4; 95% CI -3.3 to -2.4 in placebo; p[0.02). Qmax growth was 2.5AE4.3 ml/s (vs. 1.4AE3.3 in placebo; p[0.049), TPV reduced by 11.8AE16.0% (vs. 6.5AE14.7%; p[0.01), and PSA remained unchanged. Afalaza therapy resulted in a significant decrease in the total sum of BPH progression symptoms (p[0.01). The maximum effect of Afalaza was registered after 12 months without a tendency to form a plateau. During the study, no patient experienced AUR or BPHrelated surgery. The incidence of adverse events (AEs) did not differ between the groups, nor were there any serious AEs.
CONCLUSIONS: 12-month Afalaza therapy is effective and safe for patients with BPH/LUTS. The endpoints measurements revealed the significant advantage of Afalaza compared to placebo in the overall symptoms`benefit, decrease in TPV and a decline in the risk of BPH progression. To confirm and detail the findings further research will be provided.
Source of Funding:
The study was funded by a grant from OOO NPF MATERIA MEDICA HOLDING.
PD24-04 PREOPERATIVE PELVIC FLOOR MUSCLE EXERCISE FOR EARLY CONTINENCE AFTER HOLMIUM LASER ENUCLEATION OF THE PROSTATE: A RANDOMIZED CONTROLLED STUDY
Go Anan*, Hiromichi Iwamura, Jun Ito, Yasuhiro Kaiho, Makoto Sato, Sendai, Japan INTRODUCTION AND OBJECTIVES: Postoperative transient urinary incontinence is a bothersome complication of holmium laser enucleation of the prostate (HoLEP). The effect of preoperative pelvic floor muscle exercise (PFME) for early continence after HoLEP has never been reported. The aim of this study is to determine the benefit of preoperative and postoperative PFME for early recovery of continence.
METHODS: A randomized, prospective study was designed. Patients who underwent HoLEP were randomized to start PFME preoperatively from 28 days before HoLEP and continue postoperatively (group A) or to start PFME postoperatively alone (group B). The primary outcome measure was self-reported continence after surgery. The condition of no incontinence was evaluated by defining complete urinary control as no pad usage. The secondary outcome measure was assessed using the quality of life instrument ICIQ-SF.
RESULTS: Forty were randomized either to start PFME preoperatively and continue postoperatively (group A; n [ 20) or to start postoperative PFME (group B; n [ 20). On the patient and perioperative background, there was no difference in age, operation time, resected prostate volume, and the operator (experienced or inexperienced surgeon) in two groups. At 1 month, 35% of patients were incontinent in group A, while 45% patients were incontinent in group B (p [ 0.33). At 3 months, 5% and 35% patients were incontinent in group A and B, respectively (p [ 0.013). At 6 months, no patient was incontinent in both the groups. The postoperative ICIQ-SF scores were not significantly different between group A and B at both 1 month (6.5 vs. 6.4) and 3 months (3.5 vs. 4.6) after HoLEP (p [ 0.67). In logistic regression analysis, patients who performed preoperative PFME had a 0.52-fold lower risk of being incontinent I month after HoLEP and a 0.10-fold lower risk of being incontinent 3 months after HoLEP.
INTRODUCTION AND OBJECTIVES:
This study presents 2-year safety and efficacy data for prostatic artery embolization (PAE) to treat lower urinary tract symptoms (LUTS) caused by benign prostatic hyperplasia (BPH).
METHODS: 84 patients undergoing PAE due to LUTS caused by BPH from April 2014 through August 2018 were retrospectively reviewed. 78 of these met inclusion criteria (age>44, LUTS without retention, failed medical therapy, International Prostate Symptom Score (IPSS)>12, Quality of Life score (QOL)>2). 6 were then excluded for bladder pathology. Subjects (n[72) had mean age 71.5AE9.1, mean Charlson comorbidity index (CCI) 3.4AE1.7, mean gland volume (PGV) 167AE107mL. After PAE, subjects were evaluated at 1, 3, 6, 12 and 24 months. Comparisons to baseline used T-tests (PGV, post void residual (PVR)) and Wilcoxon signed rank tests (IPSS, QOL). Associations between IPSS, QOL or PVR and age, CCI, PGV, or median lobe enlargement were analyzed by linear regression. Adverse events were recorded using Clavien-Dindo classification.
RESULTS: Mean improvements in IPSS and QOL at 1, 3, 6, 12 and 24 months after PAE are shown in Figure 1 (P<0.001 for all). Mean improvements in PVR and PGV at 3, 6, 12 and 24 months are shown in Figure 2 (P<0.001 for all, except P[NS at 24 months). Cohort sizes diminish due to ongoing cohort maturation, dementia preventing symptom quantification, and incomplete follow-up, with 4 (6%) technical failures. There was no association between age, CCI, PGV, or median lobe enlargement and IPSS, QOL or PVR at 3, 6 or 12 months after PAE (P[NS). 2 patients had grade 2 urinary infections (with 1 death due to immunocompromise); 1 patient had painful necrotic tissue resected at 8 months; 10 patients had grade 1 adverse events.
CONCLUSIONS: PAE safely and effectively produced sustained meaningful improvements in LUTS, PVR, and PGV at 2 years, independent of age, CCI, PGV, or median lobe enlargement. BPH patients excluded from transurethral procedures by these factors may undergo PAE and expect significant symptom improvement.
Source of Funding: None.
PD24-06
PROSTATIC ARTERY EMBOLIZATION TO TREAT GROSS HEMATURIA ATTRIBUTABLE TO BENIGN PROSTATIC HYPERPLASIA: A SINGLE CENTER ANALYSIS OF 3-YEAR OUTCOMES Raj Ayyagari*, Taylor Powell, Julius Chapiro, Lawrence Staib, New Haven, CT; Shivank Bhatia, Miami, FL; Toby Chai, New Haven, CT; Steven Schoenberger, New London, CT; Ralph Devito, New Haven, CT INTRODUCTION AND OBJECTIVES: Prostatic artery embolization (PAE) is a minimally invasive angiographic procedure used to treat hematuria caused by benign prostatic hyperplasia (BPH). However scarce outcomes data exist on PAE for gross hematuria. This study
